Fresenius SE & Co KGaA (FRA:FRE) has been assigned a €81.85 ($95.17) price objective by stock analysts at Berenberg Bank in a research report issued on Tuesday. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s target price suggests a potential upside of 46.21% from the stock’s previous close.
A number of other research firms also recently weighed in on FRE. UBS Group set a €57.00 ($66.28) price objective on Fresenius SE & Co KGaA and gave the company a “sell” rating in a report on Monday, August 6th. DZ Bank restated a “buy” rating on shares of Fresenius SE & Co KGaA in a report on Tuesday, August 7th. Deutsche Bank set a €82.00 ($95.35) price objective on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Thursday, July 19th. Warburg Research set a €80.00 ($93.02) price objective on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Thursday, October 4th. Finally, Sanford C. Bernstein set a €83.00 ($96.51) price objective on Fresenius SE & Co KGaA and gave the company a “buy” rating in a report on Monday, July 9th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of €75.94 ($88.31).
Shares of FRA:FRE opened at €55.98 ($65.09) on Tuesday. Fresenius SE & Co KGaA has a 52-week low of €60.16 ($69.95) and a 52-week high of €80.00 ($93.02).
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
Recommended Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.